The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia in chronic kidney disease

INTERVENTION: 1)Febuxostat group CKD patients with hyperuricemia (Uric acid more than 6mg/dl) are scheduled to treat with 10 mg/day of febuxostat in the beginnings. The doses of febxostat are allowed to increase until 40mg/day, if the serum levels of uric acid were not controlled to the target values. 2)Allopurinol group CKD patients with hyperuricemia (Uric acid more than 6mg/dl) are scheduled to treat with 50mg/day of allopurinol in the beginnings. The dose of allopurinol is allowed to increase until 200mg/day, when the eGFR of the patients were equal or more than 50 ml/min/1.73m2. Similarly, the dose of allopurinol is allowed to increase until 100mg/day, when the eGFR of the patients were between 30 and 50 ml/min/1.73m2. CONDITION: Hyperuricemic patients with CKD PRIMARY OUTCOME: 1) Serum Uric acid; 2) Serum Cr, eGFR; 3) Derum systatin C SECONDARY OUTCOME: 1) Urinary protein/Cr ratio; 2) Urinary tubular markers/Cr ratio; 3) Urinary uric acid excretion ratio INCLUSION CRITERIA: 1)adult(older than 19 years‐old) 2)regardless of gender 3)Uric acid equal and more than 8mg/dl and the eGFR of less than 60ml/min/1.73m2 4)The general condition of the participants need to be stable. The participants should be treated according to the CKD practice guideline except uric acid treatment 5) Written informed consent should be obtained by all participants.